EUVIMEDEUVIMED entdecken
Open Access

Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance

Oren Pasvolsky, Curtis Marcoux, Denái R Milton, Mark R Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Umer R Siddiqui, Hina N Khan, Asad A Haider, Jeremy Ramdial und 12 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-05 · 26 (5) · e683-e689.e5

DOI: 10.1016/j.clml.2026.02.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-05. Verfasst von Oren Pasvolsky und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Lenalidomide, Multiple Myeloma, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For eligible patients with newly diagnosed multiple myeloma (MM), induction with bortezomib, lenalidomide, and dexamethasone (VRD) used to be the standard of care until a few years ago, when it was gradually replaced by Daratumumab + VRD (Dara-VRD), followed by autologous stem cell transplantation (autoHCT) and lenalidomide maintenance. Most patients relapse and require second-line (2L) therapy. Patients and Methods: We conducted a retrospective, single-center study of MM patients who received VRD induction, upfront autoHCT between 2005 and 2021, and lenalidomide maintenance before relapse.

Results

146 patients were included, with a median age of 60 years (range 32–80), and 39 (27%) patients had high-risk cytogenetics. Following first progression, 31% (n=45) received an immunomodulatory drug (IMiD) + proteasome inhibitor (PI)-containing triplet as 2L therapy, 21% (n=30) received an IMiD/PI-containing doublet, and 24% (n=35) received a daratumumab (Dara)-based 2L therapy. Patients receiving Dara-based regimens had higher rates of ≥VGPR (63%) compared to those receiving other regimens (IMiD+PI triplet: 35%, IMiD/PI doublet: 34%) (p=0.026). After a median follow-up of 35.8 months from 2L therapy, median PFS2 with Dara-based regimens was 59.9 months, versus 12.3 months and 11.5 months for doublets and triplets, respectively (p=0.007). Median OS from initiation of second-line therapy for the entire cohort was 52.6 months. In multivariable analysis, Dara-based therapy was associated with improved PFS2 (HR 0.35, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LenalidomideMultiple MyelomaAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationHumansFemaleMaleMiddle AgedRetrospective StudiesTransplantation, AutologousAdultAgedAged, 80 and overTreatment OutcomeMaintenance Chemotherapy

Stichwörter der Autor:innen

Multiple myelomaProgression-free survivalRelapsefirst progressionsequencing

Substanzen

LenalidomideAntibodies, Monoclonaldaratumumab

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hematology/Oncology, McGovern Medical School, The University of Texas, Health S…
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Förderung

  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute
  • University of Texas MD Anderson Cancer Center
  • Paula and Rodger Riney Foundation
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Zitieren

APA

Pasvolsky, O., Marcoux, C., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S., Saini, N., Lin, P., Siddiqui, U. R., Khan, H. N., Haider, A. A., Ramdial, J., Nieto, Y., Tang, G., Lakhani, K., Aljawai, Y., Kebriaei, P., Lee, H. C., Patel, K. K., …, & Qazilbash, M. H. (2026). Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance. Clinical Lymphoma Myeloma and Leukemia, 26(5), e683-e689.e5. https://doi.org/10.1016/j.clml.2026.02.014

Vancouver

Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, et al. Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance. Clinical Lymphoma Myeloma and Leukemia. 2026;26(5):e683-e689.e5. doi:10.1016/j.clml.2026.02.014

BibTeX
@article{Pasvolsky2026,
  author = {Pasvolsky, Oren and Marcoux, Curtis and Milton, Denái R and Tanner, Mark R and Bashir, Qaiser and Srour, Samer and Saini, Neeraj and Lin, Paul and Siddiqui, Umer R and Khan, Hina N and Haider, Asad A and Ramdial, Jeremy and Nieto, Yago and Tang, Guilin and Lakhani, Kiran and Aljawai, Yosra and Kebriaei, Partow and Lee, Hans C and Patel, Krina K and Thomas, Sheeba K and Orlowski, Robert Z and Champlin, Richard E and Shpall, Elizabeth J and Qazilbash, Muzaffar H},
  title = {Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {5},
  pages = {e683--e689.e5},
  doi = {10.1016/j.clml.2026.02.014}
}
Kostenlos starten →